Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Buspirone in depressed outpatients: a controlled study.

K Rickels1, J Amsterdam, C Clary

  • 1Department of Psychiatry, University of Pennsylvania, Philadelphia.

Psychopharmacology Bulletin
|January 1, 1990
PubMed
Summary

Buspirone treatment for major depression with anxiety showed significantly better outcomes than placebo over 8 weeks. This study found buspirone safe and well-tolerated in patients with depression and anxiety.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Pulmonary phenotypes of inborn errors of metabolism].

Revue des maladies respiratoires·2022
Same author

[Fatal nutrient deficiencies after gastric bypass].

La Revue de medecine interne·2021
Same author

Peel bond strength between 3D printing tray materials and elastomeric impression/adhesive systems: A laboratory study.

Dental materials : official publication of the Academy of Dental Materials·2020
Same author

Image Gallery: Palmar vascular lesions, a tool for diagnosis and prognosis in Fabry disease.

The British journal of dermatology·2019
Same author

[Glassy cell carcinoma of the uterine cervix: An aggressive type of cancer].

La Revue de medecine interne·2019
Same author

[Anorectal manifestations in systemic diseases].

La Revue de medecine interne·2019

Area of Science:

  • Psychiatry and Behavioral Sciences
  • Clinical Pharmacology

Background:

  • Major depression often co-occurs with significant anxiety, complicating treatment.
  • Existing treatments may have limitations in efficacy or tolerability for this patient population.

Purpose of the Study:

  • To compare the efficacy and safety of buspirone versus placebo in outpatients with major depression and anxiety.
  • To evaluate treatment response using multiple validated psychiatric rating scales.

Main Methods:

  • A double-blind, placebo-controlled study involving 155 outpatients diagnosed with major depression and significant anxiety.
  • Participants received either buspirone or placebo for 8 weeks.
  • Efficacy was assessed using the Hamilton Rating Scale for Depression (HAM-D) and its subscales, Clinical Global Impressions (CGI), and Hopkins Symptom Checklist (HSCL).

Related Experiment Videos

Main Results:

  • Buspirone treatment demonstrated significantly better efficacy than placebo across all primary outcome measures, including core depression clusters.
  • Seventy percent of patients receiving buspirone showed moderate to marked improvement compared to 35% in the placebo group (p < .01).
  • Treatment discontinuation rates were lower for buspirone (29%) than placebo (40%).

Conclusions:

  • Buspirone is an effective and well-tolerated treatment option for major depression with co-occurring anxiety.
  • The study supports the use of buspirone at doses up to 90 mg/day for this patient group.
  • Buspirone offers a favorable safety profile in managing comorbid depression and anxiety symptoms.